title: Surveillance of transmitted antiretroviral drug resistance among HIV-1 infected women attending antenatal clinics in Chitungwiza, Zimbabwe.
abstract: The rapid scale-up of highly active antiretroviral therapy (HAART) and use of single dose Nevirapine (SD NVP) for prevention of mother-to-child transmission (pMTCT) have raised fears about the emergence of resistance to the first line antiretroviral drug regimens. A cross-sectional study was conducted to determine the prevalence of primary drug resistance (PDR) in a cohort of young (<25 yrs) HAART-naïve HIV pregnant women attending antenatal clinics in Chitungwiza, Zimbabwe. Whole blood was collected in EDTA for CD4 counts, viral load, serological estimation of duration of infection using the BED Calypte assay and genotyping for drug resistance. Four hundred and seventy-one women, mean age 21 years; SD: 2.1 were enrolled into the study between 2006 and 2007. Their median CD4 count was 371cells/µL; IQR: 255-511 cells/µL. Two hundred and thirty-six samples were genotyped for drug resistance. Based on the BED assay, 27% were recently infected (RI) whilst 73% had long-term infection (LTI). Median CD4 count was higher (p<0.05) in RI than in women with LTI. Only 2 women had drug resistance mutations; protease I85V and reverse transcriptase Y181C. Prevalence of PDR in Chitungwiza, 4 years after commencement of the national ART program remained below WHO threshold limit (5%). Frequency of recent infection BED testing is consistent with high HIV acquisition during pregnancy. With the scale-up of long-term ART programs, maintenance of proper prescribing practices, continuous monitoring of patients and reinforcement of adherence may prevent the acquisition and transmission of PDR.
authors.affiliation: Department of Immunology, University of Zimbabwe College of Health Sciences, Harare, Zimbabwe. mtshabaz@gmail.com
authors.forename: Mqondisi
authors.initials: M
authors.lastname: Tshabalala
authors.forename: Justen
authors.initials: J
authors.lastname: Manasa
authors.forename: Lynn S
authors.initials: LS
authors.lastname: Zijenah
authors.forename: Simbarashe
authors.initials: S
authors.lastname: Rusakaniko
authors.forename: Gerard
authors.initials: G
authors.lastname: Kadzirange
authors.forename: Mary
authors.initials: M
authors.lastname: Mucheche
authors.forename: Seble
authors.initials: S
authors.lastname: Kassaye
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Johnston
authors.forename: David
authors.initials: D
authors.lastname: Katzenstein
mesh_terms: D000328:Adult; D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification; D006801:Humans; D011159:Population Surveillance; D019562:Viral Load; D015030:Zimbabwe / Q000453:epidemiology